Attorney Docket No. BHC 041037

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: GIELEN-HÄRTWIG, et al.

Group No.:

Serial No.: [to be assigned] National Stage of: PCT/EP2005/001487

Examiner:

Filed:

herewith

For: Heterocyclic Derivatives

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as express mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: August 25, 2006

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 **ALEXANDRIA, VA 22313-1450**

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed within three months of the filing or nationalization of this application, or before the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Reg. No. 31018

Telephone: (203) 812-2712

Date: August 25, 2006

William F. Gray

Attorney for Applicant(s)

Bayer Corporation

400 Morgan Lane

West Haven, CT 06516

10/590786

IAP12 Rec'd PCT/PTO 2 5 AUG 2006

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	Complete if Known		
•	Application Number		
INFORMATION DISCLOSURE	Filing Date	August 25, 2006	
	First Named Inventor	Gielen-Härtwig, et al.	
STATEMENT BY APPLICANT	Art Unit		
(Use as many sheets as necessary)	Examiner Name		
Sheet 1 of 2	Attorney Docket Number	BHC 041037	

Examiner Cite Initials* No.1	Document Number	U. S. PATENT DO Publication Date MM-DD-YYYY	Name of Patentee or Pages, Columns, Lin		
nitials*	itials* No.¹ Number-Kind Code² (f known)		Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
		US-			
		US-			
		US-	† -		
		US-			
		US-			
••	· · · · ·	US-			
		US-			
		US-		·	
		US-			
		US-		·	
		US-			
		US-			
		US-	 		
		US-			-
		US-	+		
		US-			
		US-			
		US-			
	\vdash	US-			

			IGN PATENT DOC	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Or Relevant Figures Appear	Т
	F1	WO 2003/053930	07/03/03	Bayer Aktiengesellschaft		Γ
	F2	WO 2004/024700	03/25/04	Bayer HealthCare AG		
						Ļ
	·					Ļ
	ŀ		,			ı

Examiner	Date	
Signature		
Signature	Considered	
	1	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Transation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/590786 IAP12 Rec'd PCT/PT0 25 AUG 2006

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** INFORMATION DISCLOSURE Filing Date August 25, 2006 STATEMENT BY APPLICANT **First Named Inventor** Gielen-Härtwig, et al. Art Unit (Use as many sheets as necessary) **Examiner Name** Attorney Docket Number Sheet αf 2 BHC 041037

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	R1	Ohmoto, et al., Development of Orally Active Nonpeptidic Inhibitors of Human Neutrophil Elastase; J. Med. Chem., 44, pp. 1268-1285 (2001)		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.